The Trump administration has announced an additional $250 million in aid to the Philippines, aimed at combating tuberculosis, improving maternal health, and addressing emerging disease threats. U.S. Secretary of State Marco Rubio revealed the funding on Thursday, highlighting the initiative as part of President Donald Trump’s new foreign aid strategy.
This announcement follows the $63 million commitment made during Trump’s meeting with Philippine President Ferdinand Marcos Jr. at the White House in July. Rubio emphasized that the aid reflects the “comprehensive bond between the United States and the Philippines” and showcases a more “efficient, time-limited, and narrowly targeted” America First approach to foreign assistance.
The Philippine embassy in Washington expressed appreciation for the aid but offered no further comments. The pledge underscores Washington’s continued strategic interest in strengthening bilateral ties with Manila while shifting away from traditional aid models such as USAID.
The Trump administration has consistently sought to reduce foreign assistance, attempting to withhold billions of dollars allocated by Congress as part of its broader “America First” policy. Despite these efforts, lawmakers, led by Republicans, have set aside billions in foreign aid funding, including $11 billion that must be allocated before the September 30 deadline.
After facing lawsuits, the administration agreed to release $6.5 billion in aid but continues to fight in court to block another $4 billion. The dispute is currently under review by the U.S. Supreme Court.
The latest pledge to the Philippines highlights Trump’s direct aid strategy, which prioritizes targeted investments in key areas while scaling back traditional multilateral pipelines. As Washington redefines its foreign assistance framework, the Philippines emerges as a key partner in regional health and security cooperation.


New Orleans Immigration Crackdown Sparks Fear as Federal Arrests Intensify
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
U.S.–Russia Peace Talks Stall as Kremlin Rejects Key Proposals
Australia Progresses AUKUS Review as U.S. Affirms Strong Support
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries
Trump Administration Tightens H-1B Visa Vetting With New Focus on Free Speech and Censorship
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Pentagon Probe Finds Hegseth’s Use of Signal Risked Exposing Sensitive Yemen Strike Details
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Senators Warn Trump Against Unauthorized Venezuela Strike, Vow War Powers Push
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 



